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In both humans and animals, the spread of Extended-Spectrum β-Lactamases
(ESBL)/AmpC producers has become a major issue, particularly due to the plasmidic
dissemination of most of these genes. Besides, over-expression of the chromosomal
ampC gene was largely reported in human and animal Enterobacteriaceae and,
more recently, modifications within the coding region of the ampC gene [encoding
Extended-spectrum AmpC β-lactamases (ESACs)] were shown to be responsible for
an hydrolysis spectrum expanded to oxyiminocephalosporins in humans. In this study,
among 6765 cattle E. coli isolates, 28 (0.37%) isolates harboring a reduced susceptibility
to cefepime (MICs ranging from 0.5 to 12μg/ml) were investigated as presumptive
ESACs producers. Highly conserved mutations in the promoter/attenuator region were
identified at positions −88, −82, −42, −18, −1, and +58. Using sequencing and cloning
experiments, amino acid substitutions of the AmpC beta-lactamase were characterized at
positions 287 (mostly S287N, but also S287C), 292 (A292V) and 296 (H296P), similarly
to data reported in humans. Interestingly, those cattle ESAC-producing E. coli isolates
predominantly belonged to the Clonal Complex (CC) 23, thus mirroring what has been
described in humans. The driving forces for the selection of ESACs in animals are
unknown, and their prevalence needs to be further investigated in the different animal
sectors. Considering the over-representation of ESAC-producing E. coli belonging to CC23
in both humans and animals, exchanges of ESAC producers between the two populations
may have occurred as well. To our best knowledge, this study is the first report of ESACs
in animals worldwide, which should be considered an emerging mechanism contributing
to the resistance to extended-spectrum cephalosporins in the animal population.
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INTRODUCTION
Escherichia coli is both a commensal and an opportunistic
pathogen of the digestive tract of mammals. E. coli is also respon-
sible for many extra-intestinal infections (ExPEC), such as those
of the urinary tract (Pitout, 2012). Concomitantly, the spread of
resistances to extended-spectrum cephalosporins (ESCs) used in
human and veterinary medicine causes major therapeutic chal-
lenges worldwide (Naseer and Sundsfjord, 2011). Indeed, in E.
coli, the vast dissemination of Extended-Spectrum β-Lactamases
(ESBLs) is a concern, in particular due to the broad success of the
CTX-M enzymes. ESBL genes are mostly plasmid-mediated and
this obviously facilitates their dissemination amongst bacteria
(Carattoli, 2008). In addition, plasmidic class C beta-lactamases
(AmpCs), such as the CMY-2 enzyme, also confer resistance to
those last-generations antibiotics and disseminate efficiently in
Enterobacteriaceae. In certain countries, a significant prevalence
of CMY-2 producers in animals has been reported (Mulvey et al.,
2009).
Numerous Enterobacteriaceae naturally produce a
chromosome-encoded AmpC cephalosporinase. In E. coli,
this enzyme is usually expressed at very low levels, as a result
of a weak promoter and a transcriptional attenuator preceeding
the ampC gene. Nevertheless, constitutive over-expression of
the chromosomal ampC gene was largely reported in clinical
isolates. This was attributed to specific spontaneous mutations
in the promoter (which creates close homologies with the E. coli
perfect consensus sequence) or the attenuator (which destabilizes
the mRNA hairpin structure) of the ampC gene. Consequently,
both mechanisms confer resistance to narrow-spectrum
cephalosporins. In human medicine, oxyminocephalosporins,
such as cefepime and cefpirome, remain usually active against
over-expressed AmpC-producing Enterobacteriaceae, thanks to
their rapid penetration through the outer membrane and poor
degradation by AmpC beta-lactamases.
More recently, nucleotides substitutions within the coding
region of the ampC gene were shown to be responsible for
an expanded hydrolysis spectrum of AmpC enzymes to oxy-
iminocephalosporins (Mammeri et al., 2004a, 2006). Amino
acid deletions or insertions (Doi et al., 2004; Mammeri et al.,
2007) of the cephalosporinase also broaden the hydrolysis spec-
trum. Those so-called Extended-Spectrum AmpC β-lactamases
(ESACs) were not only reported in E. coli, but also in other
Enterobacteriaceae, such as Enterobacter cloacae (Crichlow et al.,
1999; Barnaud et al., 2001; Vakulenko and Golemi, 2002),
Enterobacter aerogenes (Barnaud et al., 2004), Citrobacter fre-
undii (Ahmed and Shimamoto, 2008) or Serratia marcescens
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(Matsumura et al., 1998; Raimondi et al., 2001; Mammeri et al.,
2004b; Hidri et al., 2005), and even in Pseudomonas aeruginosa
and Acinetobacter baumanii (Rodriguez-Martinez et al., 2009,
2010). ESACs were considered an emerging mechanism of resis-
tance to beta-lactams and their prevalence was estimated around
0.2%, almost identical to that of plasmidic cephalosporinases
(Mammeri et al., 2008). Among the modifications of the ampC
gene in ESAC-producing E. coli, certain nucleotides substitutions
were more frequently identified, such as the S287N replace-
ment. Other replacements were found in the coding sequence
of plasmid-borne AmpCs (Kim et al., 2006), which also con-
tribute to the extension of their hydrolysis spectrum. Finally,
ESAC E. coli producers were predominantly found to belong to
the Clonal Complex (CC) 23 (Cremet et al., 2010), and this raises
the question on the selection scheme of those isolates.
To date, ESACs were reported in human isolates only. The pur-
pose of this study was thus to detect and characterize the very first
ESAC producers in animals worldwide.
MATERIALS AND METHODS
BACTERIAL ISOLATES
A total of 6765 non-replicate E. coli isolates collected from cat-
tle between February 2005 and December 2010 in France were
included in this study. They were mostly recovered from fecal
samples and from diseased animals (n = 6158), in particular
from calves severely affected with gastro-enteritidis. Those iso-
lates were recovered through the Resapath, the long-term surveil-
lance network for antimicrobial resistance in pathogenic bacteria
in France (www.resapath.anses.fr). An additional set of E. coli
isolates (n = 607) collected from healthy French cattle (carriage)
was also included. These latter isolates were recovered during a
unique sampling program at slaughterhouse in 2006–2007. All
isolates originated from various districts throughout the coun-
try and, when originating from the same district, came from
different and widely distant farms. As the definition of AmpC
over-producers may vary among studies (in particular with regard
to resistance or not to expanded-spectrum cephalosporins in
line with the strength of the ampC promoter), inclusion cri-
teria for AmpC over-production were defined as follows, i.e.,
resistance to amoxicillin and amoxicillin-clavulanic acid, resis-
tance to narrow-spectrum cephalosporins, reduced susceptibil-
ity to cefoxitin [diameter <22mm, using the criteria of the
Antibiogram Committee of the French Society for Microbiology
(CA-SFM); (www.sfm-microbiologie.fr)] and resistance to cef-
tazidime (MIC ≥6μg/ml) with a negative double-disk synergy
test. For presumptive ESAC production, a reduced susceptibility
to cefepime (MIC ≥0.5μg/ml) was further added as an inclusion
criterion.
ANTIMICROBIAL SUSCEPTIBILITY TESTING
Resistance to beta-lactams and non-beta-lactams was determined
by the disc diffusion method according to the guidelines of
the CA-SFM. E. coli ATCC 25922 was used as the quality con-
trol strain. The inhibitory effect of cloxacillin on AmpC pro-
duction was observed on plates supplemented with 200mg/L
cloxacillin (AES Chemunex, Bruz, France). MICs to cefoxitin, cef-
tazidime, cefotaxime, and cefepime were determined by E-test
(BioMérieux, Marcy l’Etoile, France) on all presumptive ESACs,
andMICs to cefoxitin, ceftazidime, cefepime, and imipenem were
also determined by E-test on the recombinant E. coli clones. As
E-tests were not available for ceftiofur, MICs to ceftiofur were
determined by broth dilution method on the recombinant E. coli
clones.
PHYLOGROUP ANALYSIS AND MOLECULAR TYPING OF E. COLI
ISOLATES
All E. coli isolates with reduced susceptibility to cefepime were
assigned to a phylogenetic group (A, B1, B2, or D) using the
PCR described by Clermont et al. (2000). Genetic relatedness of
these isolates was determined by Pulse-Field Gel Electrophoresis
(PFGE) after digestion with the BlnI restriction enzyme. Multi-
Locus Sequence Typing was performed according to the scheme
described on the E. coli MLST website (http://mlst.ucc.ie/mlst/
dbs/Ecoli).
CHARACTERIZATION AND SEQUENCE ANALYSIS OF THE
β-LACTAMASE AND ampC GENES
The blaSHV, blaTEM, blaOXA, and blaCTX−M genes were searched
by PCR as previously described (Shibata et al., 2006; Dierikx et al.,
2010). The plasmidic AmpC blaCMY−2 gene was sought using pre-
viously published primers (Mammeri et al., 2010). Chromosomal
ampC promoter mutations were detected by PCR and sequencing
of a 271 bp amplicon encompassing the −35 box, the −10 box
and the attenuator (Caroff et al., 2000). The entire ampC gene of
E. coli including its own promoter sequence was analyzed by PCR
and sequencing using the Int-B2 and Int-H1 primers (Mammeri
et al., 2006).
CLONING OF THE ampC GENES
The coding region (without the promoter) of ampC genes from
E. coli with a reduced susceptibility to cefepime was ampli-
fied with primers Int-B1 and Int-HN, as previously described
(Mammeri et al., 2006). These 1120 bp products were cloned
into pCR BluntII TOPO (Invitrogen) and the recombinant plas-
mids were transformed into E. coli strain TOP10. Transformants
were selected on plates containing kanamycin (50μg/ml) and cef-
tazidime (1μg/ml). The orientation of the insert was confirmed
by PCR with the SP6 and T7 primers in order to only keep trans-
formants with the ampC gene under the transcriptional control
of the lacZ promoter.
RESULTS
PREVALENCE OF PRESUMPTIVE ESAC PRODUCERS
Amongst the 6765 E. coli isolates studied, a total of 80 isolates
(1.18%) met the criteria of AmpC over-production, of which
71 were clinical E. coli isolates (diarrheic calves) and 9 from
healthy animals (carriage). Of them, 28 E. coli isolates harbored
an additional reduced susceptibility to cefepime (MICs rang-
ing from 0.5 to 12μg/ml) and were investigated as presumptive
ESACs producers (Table 1). MICs for ceftazidime for those 28
isolates ranged from 6 to 96μg/ml, without a positive synergy
test. Twenty-three presumptive ESACs producers (23/28, 82.1%)
were from diseased cattle and 5 (5/28, 17.9%) were from healthy
ones. None of the 28 E. coli had a plasmid-mediated blaCMY gene,
whereas 10 had a blaTEM−1 gene, 3 a blaOXA−1 gene, and 2 a
blaCTX−M−1 gene. The 28 cattle were from different geographic
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origin in France, and E. coli were genetically unrelated (using
PFGE, Table 1). However, most of them (18/28, 64.2%, Table 1)
were of sequence type (ST) 88 belonging to the CC23. ST783 and
ST1615 were also found four times each, respectively.
MUTATIONS IN THE ampC PROMOTER/ATTENUATOR AND IN THE
ampC GENE
Compared with the E. coli ATCC 25922, sequencing of
the ampC promoter revealed highly conserved mutations at
position −88, −82, −42, −18, −1, and +58. The number of
nucleotides between the novel −35 and −10 sequences was
17 bp in all isolates. Mutations in the ampC gene attenua-
tor (from +17 to +37) were frequent, particularly at position
+20, but also at +23 or +34 (Table 1). Nucleotides deletion
or insertion (at positions +1 or +33, respectively) were occa-
sionally identified. Full sequencing of the ampC gene showed
that amino acid substitutions of the AmpC beta-lactamase were
mainly detected inside or near the H-10 helix (Figure 1) at posi-
tions 287 (n = 16; mostly S287N, but also S287C), 292 (n =
2, A292V) and 296 (n = 8; H296P), but also outside this hot
spot at positions 89 (n = 1, A89T), 194 (n = 1, P194A), 215
(n = 4; A215V), 220 (n = 1; A220T), and 232 (n = 1, R232C)
(Table 1 and Figure 1). The majority of the isolates presented
one mutation in the coding sequence (n = 23), but three isolates
presented two mutations and one isolate even presented four of
them. Finally, one isolate which additionally harbored a CTX-
M enzyme presented no mutation of the ampC gene compared
the control.
CHARACTERIZATION OF THE ampC RECOMBINANT E. COLI CLONES
A subset of 7 E. coli isolates representative of the various amino
acid substitutions found alone or in combination (A215V,
A220T, S287N, S287C, A292V, H296P) and one control (15829,
strain susceptible to cefepime) were chosen for cloning exper-
iments (Table 2). PCR products of 1120 bp corresponding to
the ampC coding sequence without its promoter were cloned
into pCR BluntII TOPO. The seven recombinant plasmids were
successfully transformed into E. coli strain TOP10, giving rise
to clones TF-15166, TF-19023, TF-15816, TF-18991, TF-25456,
TF-16290, TF-20098, and TF-15829 (susceptible control). In
all recombinant plasmids, the insert was proved to be under
the transcriptional control of the lacZ promoter. MICs of
beta-lactams determined for the recombinant clones showed that
the S287N substitution had a greater impact on resistance than
S287C, H296P, and A292V (Table 2). TF-15166 and TF-19023
shared the same H296P mutation, but TF-15166 additionally
harbored an A215V mutation that did not further increase the
resistance to cefepime (MIC = 2mg/L vs. MIC = 4mg/L for TF-
19023). The A215V had also weak impact on the susceptibility to
cefepime when tested alone (TF-25456). Isolates 20098 displayed
four different mutations (A89T, P194A, A220T, R232C), which
do not increase resistance to cefepime (MIC = 0.19mg/L) and
were not found alone in the other tested isolates. TF-15829
(susceptible control) showed high MICs to ceftazidime (MIC =
24mg/L) and cefoxitin (>256mg/L) but a similar MIC value to
cefepime (MIC = 0.125mg/L) that TF-25456 or TF-20098. No
mutation in the coding sequence of the ampC gene was found in
TF-15829 compared to the reference strain.
DISCUSSION
In this study, we report the first ESAC producers in animals
worldwide. Contrary to humans (Barnaud et al., 2001; Mammeri
et al., 2004b), ESACs were exclusively searched and found in the E.
coli species. This results from the low proportion of animal infec-
tions due to other Gram negative bacteria expressing a chromo-
somal ampC gene, such as S. marcescens, E. cloacae, E. aerogenes,
A. baumanii, or P. aeruginosa (Nordmann and Mammeri, 2007).
Also, all ESAC-producing E. coli were from cattle as a result of
our study design, and further investigations are surely needed to
explore other animal sectors. The prevalence of ESAC-producing
E. coli in cattle in France was investigated over a 6-year period of
2005–2010 and estimated at 0.37% (23/6158) in clinical isolates.
Of note, this prevalence is similar to that found at a French hospi-
tal in the Paris suburb, where six ESAC producers were reported
out of 2800 E. coli isolates (0.21%) (Mammeri et al., 2008).
This prevalence is however four times higher than that found at
another French hospital, where 41 AmpC-overproducing E. coli
isolates accounted for 0.16% of all clinical E. coli isolates studied,
of which only 11 produced ESACs (Cremet et al., 2010). However,
in that study, inclusive criteria for ESAC producers included a
MIC superior or equal to 64mg/L of ceftazidime, which may have
been a factor of underestimation.
Here, ESAC producers were mostly detected in diarrheic
calves, which are also known as the main reservoir of ESBL genes
in cattle (Madec et al., 2008, 2012; Valat et al., 2012). This may
reflect the overall high antibiotic pressure with beta-lactams in
infections of the enteric tract of young animals. However, a sub-
set of 607 E. coli isolates from healthy cattle was also investigated,
which revealed an even higher ESAC prevalence compared to dis-
eased ones (5/607, 0.82%). This mirrors the situation in humans
where ESAC producers were most likely found in E. coli belong-
ing to the less pathogenic phylogroups A or B1 (Mammeri et al.,
2006; Corvec et al., 2007). Moreover, the cattle ESAC-producing
E. coli isolates predominantly belonged to the CC23, similarly to
what has been reported in humans (Cremet et al., 2010). Further
studies would be needed to understand why this evolution of the
chromosomal ampC gene of E. coli seems restricted to the same
genetic lineages in humans and animals despite different antimi-
crobial pressures and a rather host-specific distribution of the E.
coli clones.
This study also provides an overview of 23 ampC pro-
moter/attenuator sequences in cefoxitin-resistant E. coli from
cattle. Contrary to humans, reports on mutations in the ampC
promoter/attenuator regions of E. coli from animal sources are
scarce (Brinas et al., 2002; Guillouzouic et al., 2009). The poly-
morphism at positions −88, −82, −42, −18, −1, +58 found
in strong ampC promoters (Olsson et al., 1983; Guillouzouic
et al., 2009) was highly conserved in our collection. In particu-
lar, this includes the −42 mutation shown to increase ampC gene
expression (Nelson and Elisha, 1999; Caroff et al., 2000), and the
association of the −42 and −18 changes, which creates two dis-
placed new −35 and −10 boxes with an optimal 17-pb spacer
region. The −18 mutation without the −42 mutation was rare
(one isolate only) but had already been reported, in particular
in E. coli isolates which do not over-express their chromosomal
AmpC (Brinas et al., 2005). Other reported changes were not
detected here, such as mutations −32, −11, or +6 (Caroff et al.,
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FIGURE 1 | Amino acids alignments of the ESAC β-lactamases. AmpC EC2 is a published narrow-spectrum cephalosporinase that was included as a
reference strain. Point mutations are marked with a star. The two loops ( and R2) are highlighted in gray. Helix H-9, H-10, and H-11 are boxed.
Table 2 | Characteristics of the 7 E. coli transformants representative of the strains presenting a reduced susceptibility to cefepime.
Isolate Date MIC (mg/L) in transformants Mutations in the ampC sequence
CAZa FOX FEP IMI XNL
REDUCED SUSCEPTIBILITY TO CEFEPIME
TF-15166 2006 48 24 2 0.25 16 H296P, A215V
TF-19023 2007 >256 32 4 0.25 32 H296P
TF-15816 2006 >256 64 8 0.38 128 S287N
TF-18991 2007 96 32 1 0.25 64 S287C, A215V
TF-25456 2010 16 >256 0.125 0.25 32 A215V
TF-16290 2006 32 34 0.38 0.125 16 A292V
TF-20098 2007 8 48 0.19 0.5 16 A89T, P194A, A220T, R232C
SUSCEPTIBLE CONTROLS
TF-15829 2006 24 >256 0.125 0.25 64 none
TOP 10 – 0.19 4 0.023 0.19 1 none
aCAZ, ceftazidime; FOX, cefoxitin; FEP, cefepime; IMI, imipenem; XNL, ceftiofur.
2000; Corvec et al., 2002; Mulvey et al., 2005; Tracz et al., 2007).
However, these mutations might be more frequent in E. coli iso-
lates of B2 or D phylogroups, which are not well represented here
(Mammeri et al., 2008). The deletion of the entire attenuator was
not observed either (Tracz et al., 2005).
In this study, all relevant amino acid replacements found in
the ampC gene (namely S287N, S287C, A292V, and H296P)
were single substitutions, confirming that cumulating substitu-
tions in the catalytic site is not a preferential evolutionary scheme
for AmpCs, contrary to class A beta-lactamases, as previously
demonstrated (Le Turnier et al., 2009). A new A215V replace-
ment was reported here in four E. coli isolates, either as a single
or an associated mutation. This mutation, which occurs close to
the DAEX motif in the  loop, has obviously little if no impact
on the cefepime susceptibility. Indeed, in the corresponding
native isolates, reduced susceptibility to cefepime may result from
decreased permeability and/or oxacillinase production. Also, in
the recombinant clones, the wild-type ampC gene of the cefepime
susceptible control conferred the same MIC to cefepime than the
A215V replacement. Themain structural alteration found was the
S287N replacement, which occurred in the H-9 helix close to the
R2 loop. This mirrors the situation in humans where the S287N
substitution has been shown to widely contribute to the ESAC
phenotype (Mammeri et al., 2006). Similarly, other substitutions
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were also found, such as the S287C mutation, or both the H296P
or the A292V mutations inside the R2 loop. Comparison of
MICs of cefepime also confirmed that the S287N substitution
has greater impact on resistance than the others (Mammeri et al.,
2006).
Altogether this study is, to our best knowledge, the very first
report of ESACs in animals. In humans, those enzymes have likely
evolved from wild-type AmpCs by modifications in the vicin-
ity of the R1 or R2 active sites. While the ESACs described here
strongly resemble the human ones in both their genetic back-
grounds and the responsible mutations, the driving forces for the
selection of ESACs in animals are still unknown. In humans, the
ESAC phenotype frequently occurs after cefepime therapy. On
the contrary, different ESCs are used in animals, whose possi-
ble impact needs to be considered. In particular, ceftiofur is an
ESC which is widely used in animals, and elevated MICs values
to ceftiofur were found here in the recombinant E. coli clones.
Hence, the use of veterinary cephalosporins in the selection of
ESAC producers in animals might be a plausible hypothesis. Of
note, most human and animal ESAC E. coli reported so far belong
to the CC23—a well-adapted E. coli clone in the two hosts -, so
that the transfer of ESAC producers from humans to animals
may have contributed as well. Alternately, this may result from a
favorable genetic background of the ampC genes in E. coli isolates
of phylogroup A, irrespective of their human or animal origin
(Mammeri AAC 2009). Even though data in humans report simi-
lar ranges of ESACs vs. plasmidic AmpCs (Mammeri et al., 2008),
the true prevalence of ESACs in animals should be further inves-
tigated since this emerging mechanism surely contributes to the
global burden of resistance to ESCs in animals.
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